The Faculty of Medicine of the University of Geneva is seeking to fill a position of ASSOCIATE or ASSISTANT PROFESSOR in IMMUNOLOGY.
Mandatory online registration before June 30th 2018 at: http://www.unige.ch/academ
Professor of Immunology at Broegelmann Research Laboratory
A full-time permanent position as professor of immunology is vacant at the Faculty of Medicine, Broegelmann Research Laboratory, and the Department of Clinical Science. The place of work is in the Laboratory Building at Haukeland University Hospital, Bergen, Norway.
A PhD student position is available at the Faculty of Medicine, University of Iceland to study resolution of inflammation and especially the role of neutrophils in resolution of inflammation.
Two postdoc positions in Infection Immunology are available at Aarhus University (AU), Health Denmark. The position is for appointment for a two year period beginning May 1st and July 1st 2018, respectively.
For more information contact Trine Mogensen PhD DMSc, firstname.lastname@example.org
Recently, an initiative was started to establish a European network of B cell immunologists, to optimize the use of resources, exchange research ideas, train young people as experts in B cell immunology, start cooperations, and establish research groups funded by the European Union. EFIS has approved the application by Hans-Martin Jack (Germany), Rita Carsetti (Italy) and Idit Shachar (Israel) and will support the initiative for the next 4 years. The first meeting will likely be July 1-4, 2018 at the Michel Hotel in Landshut, Germany. During this first meeting, the goals and the format of future meetings (length, target group, locations etc) will be discussed and only group leaders (~80) from European countries will be invited. Therefore, the member countries should list the different groups working on B cells. Group leaders in the Denmark in the field of B cell biology who are interested in this initiative, please contact Søren Degn (email@example.com).
Søren Degn, PhD
Department of Biomedicine
Postdoctoral scientist in cancer immunotherapy (PhD, MD, pharmacist,
veterinarian or equivalent) (male/female)
Scope of the project:
We offer an exciting position in the field of tumor immunology in a highly clinically relevant research area. The focus of the group Immunopharmacology (head: PD Dr. Sebastian Kobold) is the development of new anti-tumoral immunotherapies. The postdoc will develop a novel strategy for cell-based therapy of cancer. The project is embedded in the doctoral programi-Target (Immunotargeting of Cancer) of the Elite Network of Bavaria (www.immunotarget.de) and in the Marie-Sklodowska Curie Network IMMUTRAIN, funded by the European Union.
The Division of Clinical Pharmacology (director: Prof. Stefan Endres; www.klinischepharmakologie.de) hosts doctoral students, physicians and postdocs in a young team at an internationally competitive level (Hornung et al. Science 2006; Poeck et al. Nat Med 2008 and Nat Immunol 2010; Hoffmann et al. J Hepatol 2014, Kobold et al., J Natl Cancer Inst 2015a and 2015b, Voigt et al., PNAS 2017). The Division has full training capacities and clearance for the medical board specialities clinical pharmacology and immunology.
During this project you will study events taking place during activation of the immune system. The project will combine studies on immune responses to defined nanoscale ligand patterns with the use of Single-cell RNA sequencing. Sequencing by Drop-seq allows analyses of gene expression in thousands of individual cells in a single experiment; in this project primarily B-cells will be the main cell of interest. The project will focus on the characterization of immune responses following exposure of the immune system to model antigens. The antigens in question will be generated using nanotechnologies with specific patterning of B-cell ligands. The experiments will involve in vitro experiments on presentation of such patterns to transgenic or knock-in B-cells combined with in vivo studies, including but not limited to the B1-8/NP system.
Applicants seeking further information are invited to contact:
Søren E. Degn, Department of Biomedicine, Aarhus University, firstname.lastname@example.org , Mobile: +4522141703 or Steffen Thiel, Department of Biomedicine, Aarhus University, email@example.com , Mobile: +4529270890
Application deadline by April 1st 2018
1 Group Leader (m/f)
2 Postdoctoral Researchers (m/f)
2 Research Assistants (m/f)
About BioMed X
The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics, and consumer care. These interdisciplinary project teams are conducting groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, Germany. They are working under the guidance of experienced mentors from academia and industry while expanding their scientific network and receiving entrepreneurship and leadership training.
Each BioMed X project team is sponsored by an industry partner: The sponsor of this call for application is Janssen Research & Development.
Application & Selection Process
Applications are to be made online at apply.bio.mx.
Only applications received before December 10, 2017 will be considered. As part of the online application procedure candidates will be required to enter detailed information about their previous work and submit a competitive project proposal.
The Postdoc will work on a project entitled “Resetting self-tolerance in autoimmune diabetes by proresolving mediators derived from apoptotic cell efferocytosis”. Type 1 diabetes (T1D) is a chronic autoimmune disease resulting from the selective destruction of insulin-secreting pancreatic β-cells by autoreactive T lymphocytes. We hypothesize that administration of pro-resolving mediators, issued from apoptotic cell phagocytosis by macrophages (called efferocytosis), may constitute a promising strategy for controlling the dysregulated immune responses characteristic of T1D. Our research program will use both the non-obese diabetic (NOD) mouse model and samples from T1D patients. Our first objective is to assess the capacity of NOD macrophages to produce pro-resolving mediators after apoptotic cell efferocytosis. A strong focus will be brought on immunomodulatory cytokines and lipid subclasses
(lipidomic approach). The second objective is to evaluate the therapeutic effect of the pro-resolving mediators in autoimmune diabetes (NOD mouse model). Third, production of human pro-resolutive factors from T1D and healthy subjects will be compared to identify biomarkers of T1D.